Knight Therapeutics (TSX:GUD) Total Liabilities : C$198.6 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Knight Therapeutics Total Liabilities?

Knight Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was C$198.6 Mil.

Knight Therapeutics's quarterly Total Liabilities declined from Jun. 2023 (C$206.54 Mil) to Sep. 2023 (C$196.48 Mil) but then increased from Sep. 2023 (C$196.48 Mil) to Dec. 2023 (C$198.62 Mil).

Knight Therapeutics's annual Total Liabilities increased from Dec. 2021 (C$149.87 Mil) to Dec. 2022 (C$228.98 Mil) but then declined from Dec. 2022 (C$228.98 Mil) to Dec. 2023 (C$198.62 Mil).

Knight Therapeutics Total Liabilities Historical Data

The historical data trend for Knight Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Knight Therapeutics Total Liabilities Chart

Knight Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

390.20

153.44

149.87

228.98

198.62

Knight Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															228.98	225.91	206.54	196.48	198.62

Knight Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Knight Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	114.029	+	(49.513	+	32.263
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.817	+	0)
	=	198.6

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	945.493	-	746.871
	=	198.6

Knight Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	114.029	+	(49.513	+	32.263
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	2.817	+	0)
	=	198.6

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	945.493	-	746.871
	=	198.6

Knight Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Knight Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Knight Therapeutics (TSX:GUD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Knight Therapeutics Inc (TSX:GUD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

KHTRF:USA

Address

3400 De Maisonneuve West, Suite 1055, Montreal, QC, CAN, H3Z 3B8

Website

https://www.gud-knight.com

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Ltin America and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Executives

Sime Armoyan

10% Security Holder

Knight Therapeutics (TSX:GUD) Headlines

No Headlines